Overview

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis
Phase:
Phase 1
Details
Lead Sponsor:
Akros Pharma Inc.